|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 05:00pm | UK inflation rises; Barratt cuts completions outlook | AN |
| 03:00pm | AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down | MT |
| Market Cap | 74.29B 100B 86.78B 82.06B 139B 9,610B 140B 979B 377B 4,873B 376B 368B 15,540B | P/E 2026 * |
14.2x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 94.97B 128B 111B 105B 178B 12,285B 180B 1,252B 482B 6,229B 481B 470B 19,866B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.6x |
| Free-Float |
92.75% | Yield 2026 * |
3.75% | Yield 2027 * | 4.04% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.19% | +1.09% | +51.85% | +97.36% | 1,013B | ||
| +0.33% | -0.71% | +50.62% | +65.50% | 644B | ||
| +0.49% | +5.73% | +20.88% | +72.92% | 465B | ||
| +0.32% | +4.52% | +40.63% | +40.88% | 352B | ||
| +1.21% | +3.28% | +19.03% | +25.32% | 264B | ||
| +0.64% | +4.91% | +7.72% | +13.93% | 253B | ||
| -1.53% | -4.46% | +36.90% | +44.08% | 203B | ||
| +0.30% | -4.03% | -22.79% | -57.37% | 188B | ||
| -0.08% | -0.23% | +30.00% | +93.34% | 181B | ||
| Average | +0.18% | -1.08% | +26.09% | +43.99% | 395.97B | |
| Weighted average by Cap. | +0.21% | +0.01% | +35.00% | +60.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.93B 45.76B 39.64B 37.48B 63.69B 4,390B 64.17B 447B 172B 2,226B 172B 168B 7,098B | 35.5B 47.88B 41.47B 39.22B 66.63B 4,593B 67.14B 468B 180B 2,329B 180B 176B 7,427B |
| Net income | 5.35B 7.21B 6.25B 5.91B 10.04B 692B 10.11B 70.49B 27.12B 351B 27.09B 26.49B 1,119B | 6.28B 8.47B 7.34B 6.94B 11.79B 813B 11.88B 82.83B 31.87B 412B 31.83B 31.13B 1,315B |
| Net Debt | 20.68B 27.89B 24.16B 22.84B 38.81B 2,675B 39.11B 273B 105B 1,357B 105B 102B 4,326B | 17.97B 24.23B 20.99B 19.85B 33.72B 2,324B 33.98B 237B 91.12B 1,179B 91.02B 89B 3,759B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions

















